Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1

Interventions

pembrolizumab 126Cisplatin 48Cetuximab 46Nivolumab 36Carboplatin 33Paclitaxel 28Fluorouracil 26Docetaxel 17Cyclophosphamide 12avelumab 11Radiotherapy 11cemiplimab 10atezolizumab 10durvalumab 9Ipilimumab 8spartalizumab 7fludarabine 7budigalimab 7Gemcitabine 7Capecitabine 7tremelimumab 6lenvatinib 6Pemetrexed 6130-nm albumin-bound paclitaxel 6epacadostat 5Fulvestrant 5zimberelimab 4tislelizumab 4Trastuzumab 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Carcinoma of Head and Neck × yeast-CEA vaccine × Clear all
NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡